Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2004

View Archived Issues

Enhancement of memory T-cells may improve vaccine therapies

New approvals for tamsulosin formulations

Promising results with small molecule MIF inhibitors in a preclinical model of colitis

Taiho patent covers new antiarthritic agents

Novel HDL-increasing agents developed at Eisai

Novel PDE4 inhibitors prepared and tested at Kyowa Hakko

Oxazepine-based antitumor agents newly discovered at Servier

Novel DPP-IV inhibitors and their use in type 2 diabetes claimed by Merck

New antitumor, antibacterial and antifungal agents isolated from Streptomyces sp.

Pfizer researchers describe new cannabinoid CB1 antagonists

Micrologix Biotech changes name to Migenix

Introgen Therapeutics receives NCI grant to further mda-7 gene research

Ceregene begins phase I trial of novel gene therapy for Alzheimer's disease

GSK grants Kenyan company license for manufacture and sale of HIV/AIDS medicines in Africa

Pharmion's MAA for Vidaza accepted for review by EMEA

Good safety profile reported for the NYVAC-HIVC vaccine in healthy volunteers

Phase II trial of Infecton for the detection of bacterial osteomyelitis initiated

Therapeutic benefits of SomatoKine in a child with Leprechaunism

E.U. approves Xenical label change

Clinical evidence for the efficacy of topiramate in the prevention of migraine

CytoVax and Millenium enter into definitive merger agreement

Phase I study for novel antibiotic WAP-8294A2 commences in U.S.

Fast track designation for Aurexis

FDA grants priority review to investigational female testosterone patch

Roche and Glycart to discover next-generation therapeutic antibodies

Enrollment completed for U.S. phase II Psoraxine study

GW-274150 reduces experimental neuropathic hypersensitivity

In vivo effects of capsaicin reduced by GW-833972

AF-3191 effective in preclinical pain models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...